Jade Biosciences (JBIO) AI Stock Analysis

• Market Cap: $685.00M
• Dividend Yield: 14.68%
• Average Volume (3M): 127.19K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.14
• Revenue Growth: N/A
• EPS Growth: 89.16%
• Country: US
• Employees: 50
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.45
• Shares Outstanding: 49,316,288
• 10 Day Avg. Volume: 252,880
• 30 Day Avg. Volume: 127,195
• PEG Ratio: 0.04
• Price to Book (P/B): 1.46
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.10
• Enterprise Value/Market Cap: 0.53
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -16.61K
• Enterprise Value/Ebitda: -3.96
• 1Y Price Target: $28.27
• Price Target Upside: 101.93% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8
• EPS Forecast (FY): -2.08
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: $14.00 ▲(0.00% Upside)
• Action: Reiterated Date: 03/08/26
• Date: Action: Reiterated 03/08/26

JBIO scores as a mid-range, higher-risk biotech: strong capitalization/low leverage and a runway-supportive strategic update are positives, but the overall score is held back by no reported revenue, widening losses, and sustained cash burn. Technical indicators are also modestly bearish, adding near-term risk.

Positive Factors

Balance sheet strength

Very low debt versus substantial equity and a sharp asset increase provide durable financial flexibility for R&D spending and reduce near-term solvency risk. This capital base supports multi-year clinical programs and lowers the probability of distress-driven strategic constraints while trials progress.

Cash runway into H1 2028

A multi-year cash runway materially lowers short-term financing pressure and gives management time to advance multiple clinical programs to key readouts. This supports execution of planned Phase 1/2 milestones and reduces the immediacy of dilution risk while programs are de-risked by data.

Advancing diversified pipeline

Multiple programs across stages diversify binary risk and create several independent value inflection points. Progressing JADE101/201/301 through Phase 1/2 positions the company to de-risk candidates via clinical data, increasing options for partnerships or staged commercialization strategies.

Negative Factors

No reported revenue

Absence of commercial revenue means the business lacks operational cash generation and product-market validation, forcing reliance on capital markets or partners. Until a product reaches commercialization, revenue risk persists and valuation depends entirely on future clinical success.

Large and growing cash burn

Sustained ~-$95M annual operating outflow strains resources over time and necessitates further funding or cutbacks absent revenue. Persistent burn raises dilution risk and could force reprioritization of programs if spending outpaces capital raises or cash runway assumptions change.

Dependence on external funding and clinical outcomes

Reliance on external capital combined with binary clinical milestones makes future financing likely and outcomes-driven. Failures or delays could materially alter strategy, increase dilution, or slow development, creating structural execution and funding risk until commercialization is achieved.

Jade Biosciences Business Overview & Revenue Model

Company Description

Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026. The company's pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.

How the Company Makes Money

Aerovate Therapeutics makes money primarily through the development and commercialization of its therapeutic products. The company aims to generate revenue by bringing its lead product candidate, AV-101, to market, pending successful clinical trials and regulatory approval. Revenue streams are expected to include sales of AV-101 upon commercialization, potential partnerships or collaborations with other pharmaceutical companies, and licensing agreements that may provide upfront payments, milestone payments, and royalties. Additionally, Aerovate may seek grants or funding from health organizations to support its research and development efforts.

Jade Biosciences Financial Statement Overview

Summary

Balance sheet strength (minimal debt vs. ~$332.5M equity and sharply higher assets in 2025) is a clear positive, but operating fundamentals remain very weak with $0 revenue across 2020–2025, widening losses (net income to about -$127.4M in 2025), and large ongoing cash burn (2025 operating cash flow about -$94.7M).

Income Statement

The income statement remains very weak: the company reports $0 revenue across all provided annual periods (2020–2025), while losses have expanded meaningfully, with net income declining from about -$9.6M (2020) to -$127.4M (2025). Operating losses (EBIT/EBITDA) also widened materially in 2025 versus 2024, indicating higher spending without an offsetting revenue base. A key positive is that losses are being driven by investment rather than debt costs (given very low debt), but profitability and business traction are not yet evident in the reported figures.

Balance Sheet

The balance sheet is a relative strength: leverage is minimal, with total debt of ~$0.7M against stockholders’ equity of ~$332.5M in 2025 (very low debt relative to equity). Total assets increased sharply to ~$349.8M in 2025 from ~$80.3M in 2024, suggesting significant capitalization/funding activity. The main weakness is negative returns on equity driven by persistent losses (2025 return on equity is meaningfully negative), which will pressure the equity base over time if cash burn continues.

Cash Flow

Cash flow is pressured by sustained cash burn: operating cash flow and free cash flow are negative every year provided, with 2025 operating cash flow at about -$94.7M and free cash flow at about -$94.9M. While free cash flow improved versus 2024 (less negative, reflected in positive free cash flow growth in 2025), the absolute level of outflow remains large and consistent with an early-stage biotech profile. A modest positive is that free cash flow roughly tracks net loss (free cash flow is approximately in line with net income), but the company still appears dependent on external funding until revenues emerge.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-26.00K	-282.00K	-96.00K	-68.00K	-15.00K
EBITDA	-113.54M	-69.29M	-75.37M	-51.42M	-22.95M
Net Income	-127.41M	-69.63M	-75.52M	-51.51M	-22.96M
Balance Sheet
Total Assets	349.78M	80.33M	127.42M	135.30M	175.36M
Cash, Cash Equivalents and Short-Term Investments	336.16M	78.62M	122.44M	129.22M	167.38M
Total Debt	724.00K	417.00K	675.00K	1.09M	574.00K
Total Liabilities	17.26M	3.90M	17.96M	8.56M	2.94M
Stockholders Equity	332.52M	76.43M	109.46M	126.74M	172.42M
Cash Flow
Free Cash Flow	-94.89M	-71.20M	-56.92M	-39.32M	-27.58M
Operating Cash Flow	-94.69M	-71.20M	-56.78M	-39.12M	-27.40M
Investing Cash Flow	-247.01M	56.03M	11.88M	6.93M	-113.43M
Financing Cash Flow	360.77M	25.43M	46.00M	396.00K	190.46M

Jade Biosciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 14.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JBIO, the sentiment is Negative. The current price of 14 is below the 20-day moving average (MA) of 14.12, below the 50-day MA of 14.69, and above the 200-day MA of 11.09, indicating a neutral trend. The MACD of -0.19 indicates Negative momentum. The RSI at 45.28 is Neutral, neither overbought nor oversold. The STOCH value of 40.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JBIO.

Jade Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CLLS	54 Neutral	$252.63M	-7.16	-69.63%	―	158.54%	66.90%
TECX	54 Neutral	$552.78M	-5.15	-26.87%	―	―	60.40%
JBIO	52 Neutral	$685.00M	-3.80	-50.23%	14.68%	―	89.16%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GALT	46 Neutral	$184.41M	-8.32	32.59%	―	―	18.82%
HUMA	45 Neutral	$164.10M	-3.93	853.54%	―	―	82.23%
IMMP	41 Neutral	$51.56M	―	-69.20%	―	―	-17.16%

Jade Biosciences Corporate Events

Jade Biosciences Outlines 2026 Autoimmune Pipeline Priorities

On January 5, 2026, Jade Biosciences announced its 2026 strategic priorities ahead of the J.P. Morgan Healthcare Conference, detailing plans to advance its monoclonal antibody pipeline for autoimmune diseases, including ongoing Phase 1 testing of JADE101 in healthy volunteers, the planned start of a Phase 2 trial in IgA nephropathy in mid-2026 with preliminary data in 2027, and positioning selective anti-APRIL therapy as a potential foundational treatment in IgAN. The company also outlined development timelines for JADE201, which is expected to enter a first-in-human rheumatoid arthritis study in the second quarter of 2026, and JADE301, which is in preclinical testing with a first-in-human trial planned for the first half of 2027, while providing a preliminary financial update indicating approximately $336 million in cash, cash equivalents and investments as of December 31, 2025, expected to fund operations into the first half of 2028, underscoring sufficient capital to support multiple clinical catalysts and expansion of its autoimmune pipeline.

The most recent analyst rating on (JBIO) stock is a Hold with a $17.00 price target. To see the full list of analyst forecasts on Jade Biosciences stock, see the JBIO Stock Forecast page.

Jade Biosciences Announces Private Placement Agreement

On December 13, 2025, Jade Biosciences entered into a securities purchase agreement with BB Biotech for a private placement of 3,214,286 shares of common stock at $14.00 per share, expected to raise approximately $45 million. The proceeds will fund research and development, corporate expenses, and working capital. The private placement, exempt from public offering registration, is set to close on December 16, 2025, with a registration rights agreement to file a resale registration statement with the SEC.

The most recent analyst rating on (JBIO) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Jade Biosciences stock, see the JBIO Stock Forecast page.